What the FDA labels say about taking them together
Cobicistat, elvitegravir, emtricitabine and tenofovir disoproxil and zolpidem
Cobicistat, elvitegravir, emtricitabine and tenofovir disoproxil's FDA label of February 4, 2025 names zolpidem in its drug interactions section; the zolpidem labels PlainMeds reads (4) do not name cobicistat, elvitegravir, emtricitabine and tenofovir disoproxil. The cobicistat, elvitegravir, emtricitabine and tenofovir disoproxil label: “Coadministration of parenteral midazolam with STRIBILD should be done in a setting that ensures close clinical monitoring and appropriate medical management in case of respiratory depression and/or prolonged sedation. …”
Check it at the source: the cobicistat, elvitegravir, emtricitabine and tenofovir disoproxil FDA label on DailyMed (effective February 4, 2025, Gilead Sciences, Inc.); the zolpidem FDA label on DailyMed (effective August 15, 2022, Viatris Specialty LLC).
What does the cobicistat, elvitegravir, emtricitabine and tenofovir disoproxil label say about zolpidem?
Cobicistat, elvitegravir, emtricitabine and tenofovir disoproxil label, drug interactionsConcomitant Drug Class/Drug Name: Other benzodiazepines: e.g., parenterally administered midazolam clorazepate diazepam estazolam flurazepam buspirone zolpidem; Effect on Concentration ↑=Increase, ↓=Decrease: ↑ sedatives/hypnotics; Clinical Comment: Coadministration of parenteral midazolam with STRIBILD should be done in a setting that ensures close clinical monitoring and appropriate medical management in case of respiratory depression and/or prolonged sedation. Dosage reduction for midazolam should be considered, especially if more than a single dose of midazolam is administered. With other sedative/hypnotics, dose reduction may be necessary and clinical monitoring is recommended.
Source: FDA drug label (Stribild), Gilead Sciences, Inc., effective February 4, 2025 (SPL set 74ae2a93-b267-444c-8f0f-a2a6522260ee), via openFDA; the full label on DailyMed
What does the zolpidem label say about cobicistat, elvitegravir, emtricitabine and tenofovir disoproxil?
Zolpidem's label (effective August 15, 2022) and its 3 other brand-application labels do not name cobicistat, elvitegravir, emtricitabine and tenofovir disoproxil in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Edluar), Viatris Specialty LLC, effective August 15, 2022 (SPL set a32884d0-85b5-11de-8a39-0800200c9a66), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Cobicistat, elvitegravir, emtricitabine and tenofovir disoproxil | Zolpidem | |
|---|---|---|
| Labeled for | HIV | Insomnia |
| Boxed warning | Yes | Yes |
| Pharmacy cost (NADAC) | $150.14 per tablet Stribild tablet | $0.0344 per tablet 5 mg tablet |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once